What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?

Liver Transplantation

Volumn 17, Issue SUPPL. 2, 2011, Pages

  Duvoux, Christophe ^a   Kiuchi, Tetsuya ^b   Pestalozzi, Bernhard ^c   Busuttil, Ronald ^d   Miksad, Rebecca ^e  

^a HENRI MONDOR HOSPITAL   (France)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; MITOXANTRONE; SORAFENIB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MORBIDITY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; HEALTH STATUS INDICATORS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053287635     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22367     Document Type: Note

References (45)

1. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R,. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988; 207: 373-379.
2. Ringe B, Pichlmayr R, Wittekind C, Tusch G,. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 270-285.
3. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A,. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-151. (Pubitemid 23229140)
4. Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE,. Role of liver transplantation in cancer therapy. Ann Surg 1985; 202: 401-407. (Pubitemid 16248052)
5. Ioannou GN, Perkins JD, Carithers RL Jr,. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-1351. (Pubitemid 351615357)
6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699. (Pubitemid 26079803)
7. Figueras J, Ibañez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001; 7: 877-883. (Pubitemid 33040462)
8. Bismuth H, Majno PE, Adam R,. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311-322.
9. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-7325. (Pubitemid 44911839)
10. Stone MJ, Klintmalm GB, Polter D, Husberg BS, Mennel RG, Ramsay MA, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993; 104: 196-202. (Pubitemid 23040023)
11. Cherqui D, Piedbois P, Pierga JY, Duvoux C, Vavasseur D, Tran Van-Nhieu J, et al. Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer 1994; 73: 2721-2726. (Pubitemid 24166257)
12. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533-539. (Pubitemid 34258353)
13. Hsieh CB, Chou SJ, Shih ML, Chu HC, Chu CH, Yu JC, Yao NS,. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008; 34: 906-910.
14. Olthoff KM, Rosove MH, Shackleton CR, Imagawa DK, Farmer DG, Northcross P, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1995; 221: 734-741.
15. Zhang ZH, Ma LW, Song SB, Xiu DR, Wang JJ, Yang XX, Jia YM,. Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma [in Chinese]. Zhonghua Zhong Liu Za Zhi 2005; 27: 45-47.
16. Chen GH, Lu MQ, Cai CJ, Yang Y, He XS, Zhu XF,. Clinical study of adjuvant individualized chemotherapy for hepatocellular carcinoma after liver transplantation [in Chinese]. Zhonghua Wai Ke Za Zhi 2004; 42: 1040-1043.
17. Sun J, Hou BH, Jian ZX, Ou YL, Ou JR,. Value of perioperative adjuvant therapy in liver transplantation for advanced hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 471-473.
18. Söderdahl G, Bäckman L, Isoniemi H, Cahlin C, Höckerstedt K, Broomé U, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006; 19: 288-294.
19. Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 2005; 5 (pt 1): 788-794. (Pubitemid 40461289)
20. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45: 269-276. (Pubitemid 46374583)
21. Li N, Zhou J, Weng D, Zhang C, Li L, Wang B, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13: 5847-5854. (Pubitemid 47583910)
22. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; for SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
23. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010; 40: 768-773.
24. Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F,. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010; 79: 62-66.
25. Yeganeh M, Finn RS, Saab S,. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009; 9: 2851-2854.
26. Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, Mazzaferro V,. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010; 52: 771-775.
27. Dharancy S, Romano O, Lohro R, Pageaux GP, De Ledinghen V, Hurtova M, et al. Tolerability of sorafenib in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. Liver Transpl 2008; 14 (suppl 1): S216.
28. Korangy F, Höchst B, Manns MP, Greten TF,. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010; 4: 345-353.
29. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; for Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
30. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086. (Pubitemid 32378206)
31. Klintmalm GB,. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228: 479-490. (Pubitemid 30194392)
32. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540. (Pubitemid 38443593)
33. Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25-30.
34. Marsh JW, Dvorchik I, Subotin M, Balan V, Rakela J, Popechitelev EP, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997; 26: 444-450. (Pubitemid 27328324)
35. Molmenti EP, Klintmalm GB,. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8: 736-748. (Pubitemid 35012281)
36. Plessier A, Codes L, Consigny Y, Sommacale D, Dondero F, Cortes A, et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10 (suppl 1): S86-S90. (Pubitemid 38240107)
37. Iwatsuki S, Dvorchik I, Marsh JW, Madariaga JR, Carr B, Fung JJ, Starzl TE,. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000; 191: 389-394.
38. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13: 1637-1644.
39. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543-551. (Pubitemid 46605857)
40. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-1732.
41. Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam R, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14: 956-965. (Pubitemid 352003894)
42. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
43. Punt CJ, Buyse M, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007; 99: 998-1003. (Pubitemid 47232601)
44. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al.; for Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
45. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T,. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009; 157: 258-270.